23 April 2024 in Medical Technologies. Assessment and Choice
We actualized the content and/or weight coefficients of Russian diagnosis-related groups (DRG) for inpatient and day medical care payment. Costs of medicines were calculated using actual purchase prices. Thus the weight coefficients were recalculated for several DRG including admissions for antineoplastic therapy, chronic hepatitits C treatment and treatment with the use of genetically engineered biological drugs and selective immunosupressors. Three levels of patient treatment complexity coefficients were introduced to reimburse the cost of supportive therapy in oncology. Weight coefficients for payment for radionuclide therapy were recalculated. We actualized drug therapy regimens lists covered by DRG payment. It was made for antineoplastic therapy regimens and regimens of genetically engineered drugs and selective immunosuppressors. Charges for inpatient minimally invasive operations were increased via identifying 9 new groups. Payment approaches for immunization against respiratory syncytial infection were improved. The updated grouping algorithm of cases in oncology is described.
21 June 2023 in Medical Technologies. Assessment and Choice
The content and/or weight coefficients of diagnosis-related groups for payment for medical care in a inpatient and day hospital have been updated for 2023. A significant part of changes is justified by exclusion of duplication of treatment methods in the model of diagnosis-related group and list of types of high-tech medical care. The content of oncological diagnosis-related groups including those intended to pay for therapeutic and surgical treatment of malignancies has been updated. It became possible to pay for immune phenotyping in oncohematological diseases. There are changes in formation of diagnosis-related groups to pay for treatment with genetically engineered biological drugs and selective immune suppressants. In particular, the number of groups formed according to a new classification criterion (therapy regimen and age) has been increased. New diagnosis-related group was created in order to pay for initiation of therapy in an inpatient and day hospital. Payment for immunization against respiratory syncytial viral infection has been revised, i.e. diagnosis-related groups were differentiated into 2 levels of costs depending on the age of the child. The specialists updated the content and cost of groups to pay for antimicrobial therapy of multidrug-resistant infections in addition to the main diagnosis-related group applied in accordance with the main reason for hospitalization. The approaches to payment for medical rehabilitation, in vitro fertilization, sling surgeries for urinary incontinence, chronic viral hepatitis C, phacoemulsification with intraocular lens implantation and radioiodine therapy for thyrotoxicosis have been improved. Weight coefficients of the diagnosis-related groups for payment of the treatment of a new coronavirus infection (COVID-19) were recalculated. Conditions for using complexity coefficients in the treatment of patients including drug therapy for cancer in adults have been expanded.
1 January 2022 in Medical Technologies. Assessment and Choice
Модель клинико-статистических групп (КСГ), применяемая для оплаты медицинской помощи за счет средств обязательного медицинского страхования в 2022 г., имеет ряд существенных отличий по сравнению с моделью 2021 г. Актуализированы содержание и стоимость КСГ для оплаты случаев лекарственной терапии пациентов со злокачественными новообразованиями, при этом перечни международных непатентованных наименований (МНН) и схем лекарственной терапии приведены в соответствие действующим клиническим рекомендациям; увеличено количество КСГ и изменена методика кластерного анализа при их формировании. Обновлено содержание КСГ для оплаты случаев хирургического лечения по профилю «Офтальмология» путем перемещения медицинских услуг из одной группы в другую на основе уточненного расчета стоимости. Пересмотрен подход к формированию групп профиля «Дерматовенерология»: сформированы новые КСГ, учитывающие не только диагноз, но и методы лечения дерматозов. Значительно изменены подходы к формированию КСГ для оплаты случаев лечения с применением генно-инженерных биологических препаратов и селективных иммунодепрессантов: выделено по три КСГ в условиях круглосуточного и дневного стационара на основе классификационного критерия «МНН лекарственного препарата» и числа введений. Пересмотрен подход к оплате применения антимикробной терапии при наличии инфекции, вызванной полирезистентными микроорганизмами: вместо ранее установленного коэффициента сложности лечения пациента (КСЛП) выделены три КСГ круглосуточного стационара, отнесение к которым осуществляется с учетом МНН лекарственного препарата в составе схемы антимикробной терапии. Изменены подходы к кодированию и оплате применения ботулинического токсина, в том числе при медицинской реабилитации пациентов с заболеваниями центральной нервной системы. Выделены новые КСГ для оплаты проведения иммунизации против респираторно-синцитиальной вирусной инфекции, госпитализаций в позднем посттрансплантационном периоде после трансплантации гемопоэтических стволовых клеток крови и костного мозга, актуализирована стоимость КСГ для случаев замены речевого процессора. Расширен перечень групп, для которых установлена доля заработной платы и прочих расходов, используемая в расчетах тарифов в денежном выражении. Актуализированы перечни оснований отнесения случаев лечения к прерванным, а также оплаты случаев лечения по двум и более КСГ, подходы к применению КСЛП.
23 April 2024 in Medical Technologies. Assessment and Choice
Objective. Modeling of annual cost of supportive therapy for malignant neoplasms in accordance with the guidelines of the All-Russian public organization “Russian Society of Clinical Oncology” (RUSSCO). Material and methods. The main material for modelling the cost of treatment were drug regimens presented in the RUSSCO guidelines for the following complications: chronic viral hepatitis B, hormone-mediated side effects, bone tissue pathology, immune-mediated side effects, mucositis, infusion reactions, thromboembolic complications, chronic pain syndrome, anorexia-cachexia syndrome, as well as enzyme replacement therapy for pancreatic cancer and nutritional support. To calculate population receiving anticancer drug therapy, we used data on medical billing registry database (2022). This database contains information on the number of completed cases of anticancer drug therapy and the number of appropriate patients. During the modeling, we hypothetically divided financing depending on the profiles of medical care and sources of funding. Results. The most expensive cases (87.2% of overall requirement) are treatment of bone lesions (5.532.288.615.94 rubles), thromboembolic complications (5.973.880.025.31 rubles), chronic pain syndrome (6.309.163.258.86 rubles) and nutritional support (7.009.301.585.00 rubles). Approximately 75% of the estimated funding is for «oncology» profile, i.e. treatment of complications will take place during chemotherapy period. In the current model, 47% of funding goes from the state programs of free drug supply, 28% from compulsory medical insurance to cover stay at the day and 24-hour hospitals, 23% from personal patients’ expenses. Conclusion. Modeling of supportive cancer therapy cost can underlie changes in medical care payment system.